Login to your account

Username *
Password *
Remember Me

Randomized trial: Anakinra (IL-1 receptor antagonist) does not improve outcomes in patients with mild-to-moderate COVID-19

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial – The Lancet Respiratory Medicine Commentary: The right place for IL-1 inhibition in COVID-19 – The Lancet Respiratory Medicine   Commentary on Twitter NEW Research—Anakinra did not improve outcomes in patients with mild-to-moderate #COVID19 pneumonia […]

The post Randomized trial: Anakinra (IL-1 receptor antagonist) does not improve outcomes in patients with mild-to-moderate COVID-19 appeared first on Links Medicus.

[Press Release – Not Published Yet] Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients

Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients – National Institutes of Health  

The post [Press Release – Not Published Yet] Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients appeared first on Links Medicus.

[Press Release – Not Published Yet] Colchicine reduces the risk of COVID-19-related complications: Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients

Colchicine reduces the risk of COVID-19-related complications: Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients – Montreal Heart Insititute Study Protocol: Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) (COVID-19) – ClinicalTrials.gov “Patients will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first […]

The post [Press Release – Not Published Yet] Colchicine reduces the risk of COVID-19-related complications: Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients appeared first on Links Medicus.

Randomized trial: Benralizumab effects on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)   Commentary on Twitter NEW Research—#Benralizumab significantly reduced exacerbation […]

The post Randomized trial: Benralizumab effects on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma appeared first on Links Medicus.

Twenty articles that critical care clinicians should read about COVID-19

Twenty articles that critical care clinicians should read about COVID-19 – Intensive Care Medicine   Commentary on Twitter Main early papers on #COVID19 & their findings, an overview:➡️ manifestations of severe disease➡️ pharmacological therapy➡️ ventilatory support in pts with #SARSCoV2 related #ARDS➡️ healthcare organization & healthcare worker stress#FOAMcc #COVIDFOAM https://t.co/PvwsKhHn9v pic.twitter.com/QVg4zXU5TT — Intens Care Med […]

The post Twenty articles that critical care clinicians should read about COVID-19 appeared first on Links Medicus.

Patients, clinicians seek answers to the mystery of ‘Long COVID’

Patients, clinicians seek answers to the mystery of ‘Long COVID’ – CIDRAP  

The post Patients, clinicians seek answers to the mystery of ‘Long COVID’ appeared first on Links Medicus.

Clinical update: Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine – JAMA Author interview: COVID-19 Vaccine Safety–Anaphylaxis and Allergic Reactions  

The post Clinical update: Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine appeared first on Links Medicus.

Large cohort study identifies the most common hospital complications associated with COVID-19

Diagnosis-wide analysis of COVID-19 complications: an exposure-crossover study – Canadian Medical Association Journal Commentaries: Analysis of patient data reveals most common complications of COVID-19 – Medical News Today AND Study confirms most common complications associated with COVID-19 – New Medical   Commentary on Twitter Large study of patients in the US who contracted #COVID19 confirms […]

The post Large cohort study identifies the most common hospital complications associated with COVID-19 appeared first on Links Medicus.

Airborne transmission of SARS-CoV-2: What we know

Airborne Transmission of SARS-CoV-2: What We Know – Clinical Infectious Diseases   Commentary on Twitter Our workshop summary on airborne transmission of SARS-CoV-2 is out. Thanks to all the leading scientists who helped lead this amazing and impactful workshop! @theNASEM @linseymarr @kprather88 @Lakdawala_Lab https://t.co/MKfNA0QatN — John Volckens (@Smogdr) January 18, 2021  

The post Airborne transmission of SARS-CoV-2: What we know appeared first on Links Medicus.

[News release – Not published yet] Lilly’s neutralizing antibody prevented COVID-19 at nursing homes, reducing risk by up to 80 percent for residents

Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents Commentaries: Eli Lilly says its monoclonal antibody prevented Covid-19 infections in clinical trial – STAT AND Expert reaction to press release from Lilly about their neutralising antibody bamlanivimab and results from the […]

The post [News release – Not published yet] Lilly’s neutralizing antibody prevented COVID-19 at nursing homes, reducing risk by up to 80 percent for residents appeared first on Links Medicus.